1. Medtech Insight
  2. >>Geography
  3. >>Asia

Japan Regulatory Update: More In-Depth Data Demands; Single-Audit Participation

Japan's regulatory authority plans to establish a new Regulatory Science Centre in the next three years, which will be tasked with reviewing more in-depth data to support product approvals. Also, the country is now a full participant in the Medical Device Single Audit Program.

Medical device and drug companies will be required to submit more in-depth data to get product approval in Japan, as the country’s Pharmaceuticals and Medical Devices Agency looks to introduce "advanced" product evaluations within the next several years.

The effort would be run by a new Regulatory Science Centre that will be established within PMDA to support product reviews. RSC would be tasked with applying advanced regulatory science...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Asia

More from Geography

EU Finalizes Framework For Joint Clinical Assessments Of High-Risk Devices

 
• By Amanda Maxwell

Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.

Get Ready For International Harmonization Before Approaching QMSR Deadline, Says Regulatory Expert

 
• By Brian Bossetta

During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.

UK Take Care! Regulatory And Market Access Reforms Must Not Shut Out Medtech Growth

 
• By Ashley Yeo

Speakers at a recent UK medtech outlook conference voiced optimism about the sector’s prospects, but warned that cost burdens, over-regulation and lengthy processes will impede the capacity of local SMEs to innovate. Only 10% of NHS procured medtech comes from UK manufacturers.